Diurnal Group PLC Posting of Annual Report and AGM Notice (4845T)

TIDMDNL

RNS Number : 4845T

Diurnal Group PLC

13 October 2017

Diurnal Group plc

("Diurnal" or the "Company")

Posting of Annual Report and AGM Notice

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that its Annual Report and Accounts for the year ending 30 June 2017, together with the notice of Annual General Meeting (AGM), have today been posted to shareholders.

The documents are being made available at the investor relations section of the Company's website, www.diurnal.co.uk.

The Company's AGM will be held at 11.30am at the offices of FTI Consulting LLP, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD on Tuesday 21 November 2017.

 
 For further information, please visit www.diurnal.co.uk 
  or contact: 
 
                                           +44 (0)20 3727 
 Diurnal Group plc                          1000 
 Martin Whitaker, Chief Executive 
  Officer 
 Richard Bungay, Chief Financial 
  Officer 
 
 Numis Securities Ltd (Nominated           +44 (0)20 7260 
  Adviser)                                  1000 
 Nominated Adviser: Michael Meade, 
  Paul Gillam, Freddie Barnfield 
 Corporate Broking: James Black 
 
 Panmure Gordon (UK) Limited (Joint        +44 (0) 20 7886 
  Broker)                                   2500 
 Corporate Finance: Freddy Crossley 
  / Duncan Monteith 
 Corporate Broking: Tom Salvesen 
 
                                           +44 (0)20 3727 
 FTI Consulting                             1000 
 Simon Conway 
 Victoria Foster Mitchell

Notes to Editors

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBSBDGIXBBGRD

(END) Dow Jones Newswires

October 13, 2017 04:00 ET (08:00 GMT)

Diurnal (LSE:DNL)
Historical Stock Chart
From Mar 2024 to Apr 2024